The search for effective cancer treatments is a never-ending battle that demands the most innovative and efficient solutions. Immunotherapy has emerged as a promising approach to combat cancer, but its complex nature and unpredictable outcomes have made it a difficult field to navigate. Unfortunately, most immunotherapy agents are not effective for 60 to 70% of cancer patients and targeting their complex immune system using in vitro screens is a daunting task.
This highlights the need for a comprehensive in vivo preclinical investigation of each new drug’s mechanism of action and efficacy for clinical applications. This is where MuScreen™ comes in, CrownBioscience’s innovative in vivo screening platform that promises to transform the way we develop immunotherapeutic drugs.
MuScreen™ offers a comprehensive suite of tools that enable scientists to test different immunotherapy medicines on mice with cancer to find the best one quickly and easily. The platform has two parts: one part tests how well the drug works on the cancer, and the other part looks at how the drug affects the mouse’s immune system. By doing so, MuScreen™ helps researchers gain a thorough understanding of a new drug’s mechanism of action and efficacy for clinical applications.
One of the key advantages of MuScreen™ is its large-scale, validated panels of homografts derived from mouse cell lines of the same inbred strain (syngeneic models) and homografts of spontaneous/ carcinogen induced GEMM (genetically engineered murine models) tumors in immunocompetent syngeneic hosts (tumor homograft models, MuPrime™). These panels can be tailored to meet specific research needs and cover a wide range of cancer types and immune profiles, making MuScreen™ a versatile and powerful tool in the fight against cancer.
In addition to its diverse range of models, MuScreen™ offers a wealth of historic data for some widely used syngeneic models, aiding support for the capabilities of the platform. The syngeneic and tumor homograft models in MuScreen™ are also comprehensively characterized, with available data including immune checkpoint inhibitor benchmarking, baseline tumor immune profile, and tumor RNAseq. Furthermore, Crown Bioscience covers the cost of the vehicle group for all models and offers a discount on shared control groups, making MuScreen™ a cost-effective solution for cancer drug development.
Maximizing the value from MuScreen™ is also possible through the FACS or Mouse I/O RNA-Seq Panel to gather further insights on immunotherapy screening. These tools enable scientists to study the pharmacodynamic effects of their immune-oncology agents, uncover predictive biomarkers, and identify patient populations that are responsive to treatment.
MuScreen™ is the most experienced, well-characterized in vivo screening platform that efficiently advances immunotherapy development. Its high-throughput and cost-effective screening across a diverse collection of immune profiles, tumor types, and mutations make MuScreen™ a distinct screening service. GVRP is the authorized distributor of Crown Bioscience services in India, and they can help you get started with MuScreen™ for your projects. With MuScreen™, the fight against cancer has never been more within reach.
Sai Supriya has a 2 year experience in academic research and fair exposure to transition into industry. She enjoys delving deep into the new developments in the biotech, pharma industry and collaborating with people. She is zealous and keen to direct her best strengths to the role by being receptive to new ideas and challenges.
Edited by: Dr Nidhi Khurana